Skip to main content

Table 1 Clinicopathologic characteristics of patients

From: LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data

Characteristics

All (n = 370, %)

LYL1 amplification (n = 22, %)

LYL1 non-amplification (n = 348, %)

P

Age, years

   

< 0.001

 Mean ± SD

63.1 ± 11.0

72.7 ± 8.0

62.5 ± 10.9

 

Menopausea

   

0.393

 Yes

313 (84.6)

0 (0)

27 (7.8)

 

 No

27 (7.3)

21 (95.5)

292 (83.9)

 Unknown

30 (8.1)

1 (4.5)

29 (8.3)

Diabetes

   

0.774

 Yes

83 (22.4)

5 (22.7)

78 (22.4)

 

 No

221 (59.7)

11 (50.0)

210 (60.3)

 Unknown

66 (17.8)

6 (27.3)

60 (17.2)

Hypertension

   

0.420

 Yes

195 (52.7)

11 (50.0)

184 (52.9)

 

 No

135 (36.5)

5 (22.7)

130 (37.4)

 Unknown

40 (10.8)

6 (27.3)

34 (9.8)

Histologic type

   

< 0.001

 Endometrioid

304 (82.2)

6 (27.3)

298 (85.6)

 

 Serous

52 (14.1)

13 (59.1)

39 (11.2)

 Mixed

14 (3.8)

3 (13.6)

11 (3.2)

Grade

   

< 0.001

 1

88 (23.8)

0 (0)

88 (25.3)

 

 2

106 (28.6)

1 (4.5)

105 (30.2)

 3

176 (47.6)

21 (95.5)

155 (44.5)

FIGO stage

   

0.003

 I

254 (68.6)

9 (40.9)

245 (70.4)

 

 II

24 (6.5)

2 (9.1)

22 (6.3)

 III

72 (19.5)

9 (40.9)

63 (18.1)

 IV

17 (4.6)

2 (9.1)

15 (4.3)

 Unknown

3 (0.8)

0 (0)

3 (0.9)

TCGA type

 POLE ultra-mutated

17 (4.6)

0 (0)

17 (4.9)

0.612

 MSI hyper-mutated

65 (17.6)

0 (0)

65 (18.7)

0.019

 Low copy number

90 (24.3)

0 (0)

90 (25.9)

0.006

 High copy-number

58 (15.7)

16 (72.7)

42 (12.1)

< 0.001

 Indeterminate

140 (37.8)

6 (27.3)

134 (38.5)

0.292

MSI status

   

< 0.001

 Stable

223 (60.2)

22 (100.0)

201 (57.8)

 

 Low

19 (5.1)

0 (0)

19 (5.5)

 High

125 (33.7)

0 (0)

125 (35.9)

 Indeterminate

3 (0.8)

0 (0)

3 (0.9)

Adjuvant treatment

 Chemotherapy only

110 (29.7)

11 (50.0)

99 (28.4)

0.032

 Radiation only

55 (14.9)

2 (9.1)

53 (15.2)

0.756

 Chemotherapy + Radiation

23 (6.2)

1 (4.5)

22 (6.3)

1.000

 Hormone therapy

17 (4.6)

0 (0)

17 (4.9)

0.612

  1. Abbreviations: FIGO International Federation of Gynecology and Obstetrics, TCGA The Cancer Genome Atlas; POLE polymerase ɛ, MSI microsatellite instability, SD standard deviation
  2. aMenopause was defined as amenorrhea for 6 months or more